Processa Pharmaceuticals company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

processapharmaceuticals.com

Founded Year

2017

About Processa Pharmaceuticals

Processa Pharmaceuticals develops products that can improve the survival and/or quality of life for patients who have a high unmet medical need.

Processa Pharmaceuticals Headquarter Location

7380 Coca Cola Drive Suite 106

Hanover, Maryland, 21076,

United States

443-776-3133

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Processa Pharmaceuticals News

Processa begins dosing in phase 1b trial of chemotherapy combo for gastrointestinal cancer

Apr 20, 2022

gorodenkoff/iStock via Getty Images Processa Pharmaceuticals (NASDAQ: PCSA ) said the first patient with advanced refractory gastrointestinal cancer was dosed in a maximum tolerated dose (MTD) phase 1b trial of next generation chemotherapy Capecitabine (a combination of PCS6422 and capecitabine). The company has amended the trial, which will provide a more precise timeline of dihydropyrimidine dehydrogenase (DPD) inhibition, among other things. The company previously said that a single dose of PSC6422 in this phase 1b trial successfully inhibited DPD, resulting in capecitabine ~50 times more potent than FDA approved capecitabine, but the improved potency did not last throughout the seven days of dosing. Combining capecitabine with PCS6422, an irreversible inhibitor of DPD, results in lower amounts of capecitabine needed to cause cell death, making the combo more potent and potentially safer, Processa (PCSA) said in an April 20 press release. "We expect to have preliminary data on a better Next Generation Capecitabine regimen by mid-2022 and anticipate that the MTD for Next Generation Capecitabine will be determined by the end of 2022. We then plan to move to either a Phase 2B or Phase 3 trial in 2023 based on our discussions with FDA,” said Processa (PCSA) Chairman and CEO David Young. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Processa Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Processa Pharmaceuticals Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.